Sanofi Pasteur to commercialize Crucell's rabies antibodies

01/3/2008 | CNNMoney

Sanofi Pasteur has agreed to collaborate with biotech firm Crucell NV for the commercialization of Crucell's rabies monoclonal antibodies. Crucell will keep its exclusive rights to distribute the final product in Europe, coexclusive distribution rights in China and the rights to sell to supranational organizations, while receiving undisclosed percentages on sales from Sanofi.

View Full Article in:

CNNMoney

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL